Diabetic Retinopathy Market By Type(Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy), By Management(Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2023-2032
-
43478
-
Jan 2022
-
155
-
-
This report was compiled by Correspondence Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page
-
Quick Navigation
- Diabetic Retinopathy Market Size, Share, Trends Analysis
- Driving Factors
- Restraining Factors
- Diabetic Retinopathy Market Segmentation Analysis
- Diabetic Retinopathy Market Segments
- Growth Opportunities
- Diabetic Retinopathy Market Regional Analysis
- Industry By Region
- Diabetic Retinopathy Market Key Player Analysis
- Diabetic Retinopathy Industry Key Players
- Diabetic Retinopathy Market Recent Development
- Report Scope
The Diabetic Retinopathy Market was valued at USD 8.16 billion in 2023. It is expected to reach USD 13.93 billion by 2033, with a CAGR of 7.37% during the forecast period from 2024 to 2033.
Diabetic patients and the need for advanced treatment methods are two key drivers behind the expansion of the diabetic retinopathy market. Diabetic retinopathy occurs most commonly among individuals living with diabetes and is caused by high blood sugar levels in their retina which causes blood vessels to swell and leak; any new blood vessel formation leads to loss of vision.
Diabetes patients are at an increased risk for vision loss - up to 25 times greater compared to individuals without diabetes. While about half of the people living with diabetes undergo regular eye exams to prevent vision loss and blindness, one-third are yet to undergo this preventive measure.
Non-proliferative, macular edema, and proliferative retinopathy are three major types of diabetic retinopathy disorder. It is the initial stage in which new blood vessels will not start spreading on the retina but in proliferative retinopathy, these new blood vessels will rapidly spread over the retina.
According to EyePoint Pharmaceutical, more than 40% of individuals are affected with retinopathy, and among that 14.6 million Americans will get affected by 2050, with vision loss complications that are affecting more than 3.4 million individuals.
They have also declared that the first patient suffering from non-proliferative retinopathy has been dosed in the phase 2 PAVIA clinical trial of EY-1901, a possible sustained supply intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment process that aims upon non-proliferative diabetic retinopathy.
Anti-VEGF treatment is used to decrease the swelling of the macula, and vision loss and might enhance the capacity of vision. This medication is in the form of injections and is given to the eyes. There is another option for preventing macular swelling i.e. steroid implants, laser treatments, and eye surgery. Advanced treatments, regular eye-checks, controlling blood sugar, and maintaining a good diet will help in preventing diabetic retinopathy and such types of medications and treatments will also help in contributing to the market expansion in the forecast period.
Driving Factors
Regular Retinal Screening Upsurges Market Demand
The escalating demand for regular retinal screening significantly contributes to the growth of the diabetic retinopathy market. As awareness of diabetic retinopathy and its potential implications on vision increases, more individuals are seeking regular retinal examinations. These screenings are crucial for early detection and treatment of diabetic retinopathy, preventing severe vision impairment.
The trend of proactive healthcare and regular monitoring, especially among the diabetic population, is driving the demand for screening services and related diagnostic equipment. This ongoing focus on preventive care is likely to continue bolstering the market, emphasizing the importance of regular eye examinations in diabetes management.
Diabetes Prevalence Spurs Market Expansion
The growing prevalence of diabetes worldwide is a primary driver of the diabetic retinopathy market's expansion. With more individuals living with diabetes comes an increase in diabetic retinopathy - one of its common complications.
An increasing diabetic population requires effective management and treatment solutions for diabetic retinopathy that include medications, laser therapies, and surgical interventions to effectively manage diabetic retinopathy. The trend suggests sustained market growth as diabetes remains a significant global health challenge, with diabetic retinopathy representing a critical aspect of diabetic care.
Geriatric Population Growth Influences Market
Older adults are more susceptible to chronic conditions like diabetes, and consequently, diabetic retinopathy. As the global population ages, the incidence of age-related health conditions, including diabetes and its complications, is expected to rise.
This demographic shift is driving the demand for specialized healthcare services, including those related to eye care and diabetic retinopathy management. The growing geriatric population points to a continued expansion of the market, as the need for comprehensive diabetic retinopathy care becomes increasingly important in aging societies.
Restraining Factors
Regulatory and Governmental Barriers Limit Diabetic Retinopathy Market Growth
Developing and introducing new treatments and diagnostic technologies often requires navigating a complex landscape of regulatory approvals and compliance with healthcare policies. This process can be time-consuming and costly, delaying the market entry of innovative solutions. Additionally, in some regions, government healthcare funding and reimbursement policies may not adequately cover diabetic retinopathy treatments, limiting patient access to these necessary services. These regulatory and financial barriers can hinder the development and widespread adoption of new treatments and technologies in the diabetic retinopathy market.
Negligence and Lack of Awareness Restrain Diabetic Retinopathy Market Expansion
Negligence and lack of awareness surrounding diabetic retinopathy severely limit market expansion. Many individuals living with diabetes are not adequately informed of the risk associated with diabetic retinopathy and its importance, thus delaying diagnosis and treatment until advanced stages become difficult to manage, leading to more expensive care plans that become harder and costlier to administer. Under-managing diabetes or not following recommended eye care protocols increases diabetic retinopathy risk, so increasing public education about its early detection and treatment; drives market expansion.
Diabetic Retinopathy Market Segmentation Analysis
By Type Analysis
Non-proliferative Diabetic Retinopathy (NPDR) is characterized by changes to retinal blood vessels, such as microaneurysms, hemorrhages, and swelling without new abnormal vessel growth, such as seen with Proliferative Diabetic Retinopathy (PDR).
NPDR is due to the rising global incidence of diabetes, poor glycemic control among diabetic patients, and its early symptoms being unnoticeable. Management for NPDR includes controlling diabetes while having regular eye examinations to prevent progression; increasing awareness and screenings are driving this market segment forward.
Proliferative Diabetic Retinopathy (PDR) is an advanced stage of diabetic retinopathy characterized by new blood vessel growth in the retina, though less common than its counterpart NPDR, it can still cause significant vision loss and blindness.
By Management Analysis
Anti-vascular endothelial Growth Factor (Anti-VEGF) treatments are the leading management option for diabetic retinopathy, particularly effective in controlling the progression of the disease. Anti-VEGF drugs, such as ranibizumab, bevacizumab, and aflibercept, work by inhibiting the growth of new blood vessels in the retina, thus preventing or slowing the progression to PDR and diabetic macular edema (DME).
This segment's dominance can be attributed to the effectiveness of these drugs in improving vision while remaining minimally invasive compared to surgical options. Growth for this sector is being spurred on by FDA approvals of new and advanced drugs, ongoing clinical trials, and increasing diabetic retinopathy prevalence rates.
Several other management options beyond medication play a crucial role in treatment. Intraocular steroid injections are used for reducing retinal swelling, especially effective in cases of Diabetic Macular Edema (DME), where they help in decreasing inflammation and improving vision. Laser surgery, a traditional treatment for diabetic retinopathy, remains effective in sealing leaking blood vessels and preventing further deterioration of vision. Vitrectomy, another surgical option, is performed in advanced stages of diabetic retinopathy, especially when there is bleeding in the vitreous humor or for repairing retinal detachment.
Diabetic Retinopathy Market Segments
By Type
- Non-proliferative Diabetic Retinopathy
- Proliferative Diabetic Retinopathy
By Management
- Anti-VEGF
- Intraocular Steroid Injection
- Laser Surgery
- Vitrectomy
Growth Opportunities
Increased Demand for Routine Retinal Screening Spurs Growth in Diabetic Retinopathy Market
As awareness of the risks associated with diabetes rises, more patients are seeking regular eye examinations to detect retinal changes early. This preventive approach is crucial for managing diabetic retinopathy, leading to a growing demand for screening services and diagnostic equipment. The trend towards regular monitoring and early detection underscores the expanding market for diagnostic and monitoring solutions specifically tailored for diabetic retinopathy.
Expansion of Emerging Therapies Enhances Diabetic Retinopathy Market
Emerging therapies for diabetic retinopathy offer tremendous growth opportunities in the market. Innovative anti-VEGF injections, laser therapy, and new surgical techniques have revolutionized how this condition is managed; with increased efficacy and safety becoming more attractive options to both healthcare providers and patients. As research continues to find more efficient, patient-friendly therapies, demand will grow for these emerging therapies due to better managing their complications.
Diabetic Retinopathy Market Regional Analysis
North America Dominates with 39.1% Market Share in Diabetic Retinopathy Market
North America holds 39.1% of the diabetic retinopathy market due to the high prevalence of diabetes across its borders - particularly the US - which correlates directly with an increase in cases of diabetic retinopathy. Advanced healthcare infrastructure and heightened awareness about diabetes and its associated complications also contribute significantly. Additionally, the region has a strong presence of leading pharmaceutical and biotech companies engaged in extensive research and development, introducing innovative treatments and technologies for diabetic retinopathy.
North American market dynamics are determined by rising healthcare expenditure and the availability of advanced medical treatments. The region's robust insurance coverage for diabetic care, including eye health, enables greater access to treatment for diabetic retinopathy. Moreover, the prevalence of routine medical screenings and regular eye examinations contributes to early diagnosis and treatment, which is crucial for managing diabetic retinopathy effectively.
Europe: Focus on Preventive Healthcare and Treatment Advancements
Europe’s diabetic retinopathy market is driven by a strong focus on preventive healthcare and advancements in treatment options. The region benefits from well-established healthcare systems and widespread awareness about diabetes management. European countries are actively investing in healthcare technologies and promoting regular screenings, aiding early detection and treatment of diabetic retinopathy.
Asia-Pacific: Rapidly Growing Market with Increasing Diabetes Prevalence
In Asia-Pacific, the diabetic retinopathy market is rapidly growing, fueled by the increasing prevalence of diabetes in densely populated countries like China and India. The region is experiencing a marked increase in healthcare awareness and facilities, propelling its market expansion. A growing middle class and improved healthcare infrastructure are expected to further fuel demand for diabetic retinopathy treatments in this area.
Industry By Region
North America
- The US
- Canada
- Rest of North America
Europe
- Germany
- France
- The UK
- Spain
- Italy
- Russia
- Netherlands
- Rest of Europe
Asia-Pacific
- China
- Japan
- South Korea
- India
- New Zealand
- Singapore
- Thailand
- Vietnam
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Rest of the Middle East & Africa
Diabetic Retinopathy Market Key Player Analysis
In the Diabetic Retinopathy Market, a specialized segment in ophthalmic treatments, the companies listed are pivotal in advancing therapeutic solutions. Bayer AG and Novartis AG are market leaders, offering innovative drugs that have set high standards in treatment efficacy. ABBVIE INC.'s strategic focus on advanced therapeutics has significantly impacted treatment modalities.
Oxurion NV and Sirnaomics specialize in novel therapeutic approaches, indicating the market's shift towards innovative, targeted treatments. Alimera Sciences and Genentech, Inc. contribute with specialized drugs, enhancing the diversity of treatment options. Ampio Pharmaceuticals Inc., BCNPeptides, and Kowa Company Ltd., though smaller in scale, provide niche solutions, showcasing the industry's focus on addressing varied aspects of diabetic retinopathy. These companies collectively drive the market, emphasizing a blend of innovation, specialization, and strategic development in tackling diabetic eye conditions.
Diabetic Retinopathy Industry Key Players
- Bayer AG
- ABBVIE INC.
- Novartis AG
- Oxurion NV
- Sirnaomics
- Alimera Sciences
- Ampio Pharmaceuticals Inc.
- BCNPeptides
- Kowa Company Ltd.
- Genentech, Inc.
Diabetic Retinopathy Market Recent Development
In November 2023, At the American Academy of Ophthalmology (AAO) meeting in 2023, Kerrie Brady, the president and chief executive officer of OcuTerra Therapeutics, shared significant progress in their Phase 2 DR: EAM (Diabetic Retinopathy Early Active Management) study. The study involves their innovative eye drop treatment called OTT166, which is a selective integrin inhibitor designed for diabetic retinopathy treatment.
In 2023, In a phase 3 trial, tarcocimab, a biopolymer with a vascular growth factor antibody, showed promising results in improving vision and anatomical markers in patients with early-stage diabetic retinopathy. This development has the potential to be a significant breakthrough in the treatment of diabetic retinopathy.
In 2023, Michigan State University (MSU) researchers found a link between cholesterol and diabetic retinopathy. They discovered that diabetes and metabolic disorders can lead to cholesterol buildup in the retina, contributing to diabetic retinopathy.
In 2023, a significant development was the creation of a transcriptomic clock to predict vascular changes associated with prodromal diabetic retinopathy. This clock is based on the gene expression patterns of 14 genes and is used to measure the severity of the progression of early retinopathy.
Report Scope
Report Features Description Market Value (2023) USD 8.16 Billion Forecast Revenue (2033) USD 13.93 Billion CAGR (2024-2032) 7.37% Base Year for Estimation 2023 Historic Period 2016-2023 Forecast Period 2024-2033 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Product Type(Eau de Parfum, Eau de Toilette, Eau de cologne, Eau Fraiche), By Product(Mass, Premium), By End-Use(Women, Men, Unisex), By Sales Channel(Online Retailers, Offline Retailers, Others) Regional Analysis North America - The US, Canada, Rest of North America, Europe - Germany, France, The UK, Spain, Italy, Russia, Netherlands, Rest of Europe, Asia-Pacific - China, Japan, South Korea, India, New Zealand, Singapore, Thailand, Vietnam, Rest of Asia Pacific, Latin America - Brazil, Mexico, Rest of Latin America, Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa Competitive Landscape Bayer AG, ABBVIE INC., Novartis AG, Oxurion NV, Sirnaomics, Alimera Sciences, Ampio Pharmaceuticals Inc., BCNPeptides, Kowa Company Ltd., Genentech, Inc. Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) -
-
- Bayer AG
- ABBVIE INC.
- Novartis AG
- Oxurion NV
- Sirnaomics
- Alimera Sciences
- Ampio Pharmaceuticals Inc.
- BCNPeptides
- Kowa Company Ltd.
- Genentech, Inc.